UPMC Health Plan & Biogen Announce Groundbreaking Value-Based Agreement For Multiple Sclerosis Treatments

UPMC Health Plan announced that it has entered into a value-based agreement with Biogen for Tecfidera® (dimethyl fumarate) and Avonex® (interferon beta-1a), two specialty medications used to treat individuals with relapsing forms of multiple sclerosis (MS). In this first-of-its-kind contract, reimbursement provided by the drug manufacturer, Biogen, to UPMC Health Plan will be linked to MS consumer-reported measures of disability progression in a real-world population.

As an integrated delivery and finance system, UPMC is uniquely positioned to administer and analyze consumer-reported clinical assessments of disability. UPMC Health Plan and collaborating specialty pharmacy . . .